Sugammadex: uses, dosing, side effects & brands
Sugammadex is a medicine sold in the U.S. under 3 brand and generic names. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Available as
- Injectable · Solution
- Sold as
- 3 products — Sugammadex, Bridion and Sugammadex Sodium
- Prescription?
- Prescription only
- Generic available?
- Yes
How Sugammadex is dosed
From the FDA label for Sugammadex (application ANDA218727). Other sugammadex products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Dosing is based on actual body weight ( 2.1 ) Monitor for twitch responses to determine the timing and dose for sugammadex injection administration. ( 2.1 ) Administer as a single bolus injection. ( 2.1 ) For rocuronium and vecuronium: 4 mg/kg is recommended if spontaneous recovery of the twitch response has reached 1 to 2 post-tetanic counts (PTC) and there are no twitch responses to train-of-four (TOF) stimulation. ( 2.2 ) 2 mg/kg is recommended if spontaneous recovery has reached the reappearance of the second twitch in response to TOF stimulation. ( 2.2 ) For rocuronium only: 16 mg/kg is recommended if there is a clinical need to reverse neuromuscular blockade soon (approximately 3 minutes) after administration of a single dose of 1.2 mg/kg of rocuronium. Immediate reversal in pediatric patients has not been studied. ( 2.2 ) 2.1 Important Dosing and Administration Information Sugammadex injection dosing is based on actual body weight. Sugammadex injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents. Doses and timing of sugammadex injection administration should be based on monitoring for twitch responses and the extent of spontaneous recovery that has occurred. Administer sugammadex injection…
Everything below is the FDA label for Sugammadex (injectable). Sugammadex is also sold as solution, and those are different medicines to take — follow the label for the one you were prescribed.
Sugammadex side effects
The following serious adverse reactions are described elsewhere in the labeling: Anaphylaxis and Hypersensitivity [see Contraindications (4) , Warnings and Precautions (5.1) ] Marked Bradycardia [see Warnings and Precautions (5.2) ] Most common adverse reactions (reported in ≥10% of adult patients at a 2, 4, or 16 mg/kg sugammadex injection dose and higher than the placebo rate): vomiting, pain, nausea, hypotension, and headache. ( 6.1 ) Most common adverse reactions (reported in ≥10% of pediatric patients 2 to <17 years of age at sugammadex injection doses of 2 or 4 mg/kg) were pain, vomiting, and nausea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Patients The data described below reflect 2914 subjects exposed to 2, 4, or 16 mg/kg sugammadex injection and 544 to placebo in pooled Phase 1 to 3 studies. The population was 18 to 92 years old, 47% male and 53% female, 34% ASA (American Society of Anesthesiologists) Class 1, 51% ASA Class 2, and 14% ASA Class 3, and 82%…
Who shouldn’t take Sugammadex
Sugammadex injection is contraindicated in patients with known hypersensitivity to sugammadex or any of its components. Hypersensitivity reactions that occurred varied from isolated skin reactions to serious systemic reactions (i.e., anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex [see Warnings and Precautions (5.1) , Adverse Reactions (6) ] . Known hypersensitivity to sugammadex or any of its components. ( 4 )
Sugammadex drug interactions
Toremifene : Concomitant use can delay recovery. ( 7.2 ) Hormonal contraceptives : Patients must use an additional, non-hormonal method of contraception for 7 days following sugammadex injection administration. ( 5.6 , 7.3 ) 7.1 Summary The information reported in sections 7.2 to 7.4 is based on binding affinity between sugammadex injection and other drugs, preclinical experiments, clinical studies and simulations of a pharmacokinetic-pharmacodynamic (PK-PD) model. Based on these considerations, no clinically significant pharmacodynamic interactions with other drugs are expected, with the exception of toremifene and hormonal contraceptives. 7.2 Interactions Potentially Affecting the Efficacy of Sugammadex Injection Toremifene For toremifene, which has a relatively high binding affinity for sugammadex and for which relatively high plasma concentrations might be present, some displacement of vecuronium or rocuronium from the complex with sugammadex injection could occur. The recovery to TOF ratio to 0.9 could therefore be delayed in patients who have received toremifene on the same day of surgery. 7.3 Interaction Potentially Affecting the Efficacy of Hormonal Contraceptives In vitro binding studies indicate that sugammadex injection may bind to progestogen, thereby decreasing progestogen exposure. Therefore, the administration of a bolus dose of sugammadex injection is considered to be equivalent to missing dose(s) of oral contraceptives containing an estrogen or progestogen. If an oral contraceptive is taken on the same day that sugammadex injection is administered, the patient must use an additional, non-hormonal contraceptive method or back-up method of contraception (such as condoms and spermicides) for the next 7 days. In the case of non-oral hormonal contraceptives, the patient must use an additional, non-hormonal contraceptive method or back-up method of contraception (such as condoms and spermicides) for the next 7 days. 7.4 Interference with Laboratory Tests Sugammadex injection may interfere with the serum progesterone assay. Interference with this test was observed at sugammadex plasma concentrations of 100 mcg/mL, which may be observed for up to 30 minutes after a 16 mg/kg dose.
Every sugammadex product we track (3)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Injectable | No data | — | View → | |
| 2 | Not yet rated | Prescription | Injectable | No data | — | View → | |
| 3 | Not yet rated | Prescription | Solution | No data | — | View → |
How long sugammadex keeps
The date on a sealed pack is not the only one: some sugammadex labels start a second clock once the product is opened or mixed, as short as 5 days.
The in-use limits sugammadex labels print, quotedSugammadex and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for sugammadex: levels in milk, effects in breastfed infants, and the drugs it would consider insteadNegligible amounts of sugammadex are excreted into breastmilk after usual doses. Because sugammadex is a large, highly polar molecule with a molecular weight of 2002 Da, oral absorption by the infant is unlikely. Sugammadex is acceptable to use during breastfeeding.
National Institute of Child Health and Human Development, record revised March 15, 2026. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about sugammadex
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 1,259 reports naming sugammadex, and the FDA flagged 95% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- anaphylactic reaction159 reports
- bradycardia80 reports
- hypotension76 reports
- anaphylactic shock68 reports
- bronchospasm55 reports
- recurrence of neuromuscular blockade41 reports
- tachycardia37 reports
- negative pressure pulmonary oedema36 reports
Read these as a signal, not a rate. A report does not mean sugammadex caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Related calculators
Frequently asked questions
What is Sugammadex?
Sugammadex is a medication supplied as an injection, solution.
Can you take sugammadex with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run sugammadex against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is sugammadex sold under?
We track 3 sugammadex-containing products in the U.S.: Sugammadex, Bridion and Sugammadex Sodium. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does sugammadex come in?
Across the brands we track, sugammadex is currently marketed as injectable and solution, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic sugammadex?
Yes. Our catalog lists 2 generic sugammadex products alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.
Cite this page
- APA
- pharmaranks. (2026, July 24). Sugammadex: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/sugammadex
- MLA
- “Sugammadex: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/sugammadex.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for sugammadex on DailyMed (NIH) ↗.